Big Rx product Does Not Reduce Risk Of Long C-19

Paxlovid Does Not Reduce Risk Of Long COVID

Study: Potentially Linked To Rebound Symptoms

By Amie Dahnke via The Epoch Times

Paxlovid, an antiviral medication prescribed to treat symptoms associated with COVID-19, does not reduce the risk of developing long COVID in vaccinated people recovering at home. 

The report comes from a new study published in the Journal of Medical Virology on Thursday. Conducted by a team of researchers from the University of California–San Francisco, the study also found that more people are experiencing rebounds of their COVID symptoms after taking Paxlovid (nirmatrelvir-ritonavir) than previously reported.

Paxlovid is the first antiviral pill approved by the U.S. Food and Drug Administration (FDA) to treat mild and moderate COVID-19 in adults. It is typically prescribed to those at high risk of having the virus progress to a severe illness, including hospitalization or death. The medication has also been authorized for use in children 12 and older who are at risk of severe outcomes from COVID-19.

According to manufacturer Pfizer, initial trials of Paxlovid showed it reduced hospitalizations and death in unvaccinated COVID patients by 86 percent to 89 percent. A real-world study conducted by the U.S. Centers for Disease Control and Prevention (CDC) showed that adults who took Paxlovid within the first five days of a COVID-19 diagnosis had a 51 percent lower hospitalization rate within 30 days than those who did not take the medication. More recent studies have indicated lower efficacy rates, with patients having about 37 percent reduced hospitalization and death risk.

In December 2022, the patients answered a follow-up survey that included questions about long COVID, COVID rebound symptoms, and how long they continued to test positive.

“We found a higher proportion with clinical rebound than previously reported, but did not identify an effect of posttreatment rebound on Long COVID symptoms,” researchers wrote.

Additionally, retesting positive was common among rebound patients; 25.7 percent of individuals who took Paxlovid and repeated antigen testing after testing negative ended up testing positive.

In all, just over 26 percent of participants reported either rebound symptoms or test positivity, the study noted.

Of the roughly 75 percent who didn’t experience rebound while on Paxlovid, 8.3 percent reported at least one long-COVID symptom.

The study echoes a Nov. 13, 2023, study conducted by Harvard Medical School (HMS) researchers also indicating that 1 in 5 individuals who took Paxlovid experienced a rebound of symptoms.

“We conducted this study to address lingering questions about Paxlovid and virologic rebound in COVID-19 treatment,” senior author Dr. Mark Siedner, associate professor of medicine at HMS and an infectious disease clinician and researcher at Massachusetts General Hospital, said in a HMS press release. “We found that the virologic rebound phenomenon was much more common than expected—in over 20 percent of people taking Paxlovid—and that individuals shed live virus when experiencing a rebound, which means they may be contagious after initial recovery.”

Previous clinical trials suggested that between 1 percent and 2 percent of patients who took Paxlovid experienced rebound, according to the press release.

**********

(TLB) published this article by Amie Dahnke as posted at The Epoch Times and also at ZeroHedge

Header featured image (edited) credit: Medication tabs/org article/Wolfgang Rattay/Reuters/Illustration

Emphasis added by (TLB)

••••

••••

Stay tuned to …

••••

The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)

••••

Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.

••••

Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.

••••

Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.